Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 458

1.

Association of Angiopoietin-2 and Ki-67 Expression with Vascular Density and Sunitinib Response in Metastatic Renal Cell Carcinoma.

Rautiola J, Lampinen A, Mirtti T, Ristimäki A, Joensuu H, Bono P, Saharinen P.

PLoS One. 2016 Apr 21;11(4):e0153745. doi: 10.1371/journal.pone.0153745. eCollection 2016.

2.

Needle biopsy through the abdominal wall for the diagnosis of gastrointestinal stromal tumour - Does it increase the risk for tumour cell seeding and recurrence?

Eriksson M, Reichardt P, Sundby Hall K, Schütte J, Cameron S, Hohenberger P, Bauer S, Leinonen M, Reichardt A, Rejmyr Davis M, Alvegård T, Joensuu H.

Eur J Cancer. 2016 May;59:128-33. doi: 10.1016/j.ejca.2016.02.021. Epub 2016 Mar 28.

PMID:
27033260
3.

Boron Neutron Capture Therapy in the Treatment of Recurrent Laryngeal Cancer.

Haapaniemi A, Kankaanranta L, Saat R, Koivunoro H, Saarilahti K, Mäkitie A, Atula T, Joensuu H.

Int J Radiat Oncol Biol Phys. 2016 May 1;95(1):404-10. doi: 10.1016/j.ijrobp.2015.11.010. Epub 2015 Nov 10.

PMID:
26797537
4.

[Triumphal march of cancer therapy goes on].

Joensuu H.

Duodecim. 2015;131(22):2163-70. Review. Finnish.

PMID:
26749910
5.

Improved Treatment of Breast Cancer with Anti-HER2 Therapy Requires Interleukin-21 Signaling in CD8+ T Cells.

Mittal D, Caramia F, Michiels S, Joensuu H, Kellokumpu-Lehtinen PL, Sotiriou C, Loi S, Smyth MJ.

Cancer Res. 2016 Jan 15;76(2):264-74. doi: 10.1158/0008-5472.CAN-15-1567. Epub 2016 Jan 7.

PMID:
26744522
6.

Quantification of Estrogen Receptor-Alpha Expression in Human Breast Carcinomas With a Miniaturized, Low-Cost Digital Microscope: A Comparison with a High-End Whole Slide-Scanner.

Holmström O, Linder N, Lundin M, Moilanen H, Suutala A, Turkki R, Joensuu H, Isola J, Diwan V, Lundin J.

PLoS One. 2015 Dec 14;10(12):e0144688. doi: 10.1371/journal.pone.0144688. eCollection 2015.

7.

Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): a randomised, open-label, multicentre, phase 2 trial.

Cortés J, Dieras V, Ro J, Barriere J, Bachelot T, Hurvitz S, Le Rhun E, Espié M, Kim SB, Schneeweiss A, Sohn JH, Nabholtz JM, Kellokumpu-Lehtinen PL, Taguchi J, Piacentini F, Ciruelos E, Bono P, Ould-Kaci M, Roux F, Joensuu H.

Lancet Oncol. 2015 Dec;16(16):1700-10. doi: 10.1016/S1470-2045(15)00373-3. Epub 2015 Nov 17.

PMID:
26596672
8.

Adjuvant Imatinib for High-Risk GI Stromal Tumor: Analysis of a Randomized Trial.

Joensuu H, Eriksson M, Sundby Hall K, Reichardt A, Hartmann JT, Pink D, Ramadori G, Hohenberger P, Al-Batran SE, Schlemmer M, Bauer S, Wardelmann E, Nilsson B, Sihto H, Bono P, Kallio R, Junnila J, Alvegård T, Reichardt P.

J Clin Oncol. 2016 Jan 20;34(3):244-50. doi: 10.1200/JCO.2015.62.9170. Epub 2015 Nov 2.

PMID:
26527782
9.

Breast cancer prognosis and isolated tumor cell findings in axillary lymph nodes after core needle biopsy and fine needle aspiration cytology: Biopsy method and breast cancer outcome.

Liikanen J, Leidenius M, Joensuu H, Vironen J, Heikkilä P, Meretoja T.

Eur J Surg Oncol. 2016 Jan;42(1):64-70. doi: 10.1016/j.ejso.2015.08.170. Epub 2015 Sep 25.

PMID:
26427542
10.

Comment on ESMO Magnitude of Clinical Benefit Scale.

Muhonen T, Joensuu H, Pfeiffer P.

Ann Oncol. 2015 Dec;26(12):2504. doi: 10.1093/annonc/mdv384. Epub 2015 Sep 14. No abstract available.

PMID:
26371286
11.

Biokinetic analysis of tissue boron (¹⁰B) concentrations of glioma patients treated with BNCT in Finland.

Koivunoro H, Hippeläinen E, Auterinen I, Kankaanranta L, Kulvik M, Laakso J, Seppälä T, Savolainen S, Joensuu H.

Appl Radiat Isot. 2015 Dec;106:189-94. doi: 10.1016/j.apradiso.2015.08.014. Epub 2015 Aug 14.

PMID:
26363564
12.

Integrative proteomic and gene expression analysis identify potential biomarkers for adjuvant trastuzumab resistance: analysis from the Fin-her phase III randomized trial.

Sonnenblick A, Brohée S, Fumagalli D, Rothé F, Vincent D, Ignatiadis M, Desmedt C, Salgado R, Sirtaine N, Loi S, Neven P, Loibl S, Denkert C, Joensuu H, Piccart M, Sotiriou C.

Oncotarget. 2015 Oct 6;6(30):30306-16. doi: 10.18632/oncotarget.5080.

13.

[Adjuvant drug therapies for breast cancer].

Huovinen R, Auvinen P, Mattson J, Joensuu H.

Duodecim. 2015;131(1):23-8. Review. Finnish.

PMID:
26245052
14.

Levonorgestrel-releasing intrauterine system and the risk of breast cancer: A nationwide cohort study.

Soini T, Hurskainen R, Grénman S, Mäenpää J, Paavonen J, Joensuu H, Pukkala E.

Acta Oncol. 2016 Feb;55(2):188-92. doi: 10.3109/0284186X.2015.1062538. Epub 2015 Aug 4.

PMID:
26243443
15.

Human breast cancer cells educate macrophages toward the M2 activation status.

Sousa S, Brion R, Lintunen M, Kronqvist P, Sandholm J, Mönkkönen J, Kellokumpu-Lehtinen PL, Lauttia S, Tynninen O, Joensuu H, Heymann D, Määttä JA.

Breast Cancer Res. 2015 Aug 5;17:101. doi: 10.1186/s13058-015-0621-0.

16.

Constitutive phosphorylated STAT3-associated gene signature is predictive for trastuzumab resistance in primary HER2-positive breast cancer.

Sonnenblick A, Brohée S, Fumagalli D, Vincent D, Venet D, Ignatiadis M, Salgado R, Van den Eynden G, Rothé F, Desmedt C, Neven P, Loibl S, Denkert C, Joensuu H, Loi S, Sirtaine N, Kellokumpu-Lehtinen PL, Piccart M, Sotiriou C.

BMC Med. 2015 Aug 3;13:177. doi: 10.1186/s12916-015-0416-2.

17.

Radiotherapy for GIST progressing during or after tyrosine kinase inhibitor therapy: A prospective study.

Joensuu H, Eriksson M, Collan J, Balk MH, Leyvraz S, Montemurro M.

Radiother Oncol. 2015 Aug;116(2):233-8. doi: 10.1016/j.radonc.2015.07.025. Epub 2015 Jul 27.

18.

Physician Estimations of the Risk of Gastrointestinal Stromal Tumor Recurrence--Not Accurate Enough?: More Education May Be Needed.

Joensuu H.

JAMA Oncol. 2015 Sep;1(6):805-6. doi: 10.1001/jamaoncol.2015.2404. No abstract available.

PMID:
26203794
19.
20.

Deregulated hepsin protease activity confers oncogenicity by concomitantly augmenting HGF/MET signalling and disrupting epithelial cohesion.

Tervonen TA, Belitškin D, Pant SM, Englund JI, Marques E, Ala-Hongisto H, Nevalaita L, Sihto H, Heikkilä P, Leidenius M, Hewitson K, Ramachandra M, Moilanen A, Joensuu H, Kovanen PE, Poso A, Klefström J.

Oncogene. 2016 Apr 7;35(14):1832-46. doi: 10.1038/onc.2015.248. Epub 2015 Jul 13.

PMID:
26165838
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk